RJA
BIIB icon

Ross\Johnson & Associates’s Biogen BIIB Stock Holding History

Ross\Johnson & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$183 Hold
1
– – ﹤0.01% 178
2025
Q4 		$176 Hold
1
– – ﹤0.01% 259
2025
Q3 		$140 Hold
1
– – ﹤0.01% 192
2025
Q2 		$126 Hold
1
– – ﹤0.01% 192
2025
Q1 		$136 Buy
+1
New +$143 ﹤0.01% 335

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ross\Johnson & Associates's BIIB Position: Q1 2026 in Review

Ross\Johnson & Associates held its Biogen (BIIB) position steady in Q1 2026 at 1 share worth $183. The position accounts for ﹤0.01% of the portfolio, ranked #178.

Ross\Johnson & Associates first reported a position in BIIB in Q1 2025 and has held it in 5 quarters since. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Ross\Johnson & Associates held 1 share of Biogen worth $183 as of Q1 2026.
  • Ross\Johnson & Associates left its Biogen share count unchanged in Q1 2026.
  • Biogen made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q1 2026, its #178 holding.
  • Ross\Johnson & Associates first reported a position in Biogen in Q1 2025 and has held it in 5 quarters since.
  • 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.